Compare SCLX & HGBL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCLX | HGBL |
|---|---|---|
| Founded | 2011 | 1937 |
| Country | United States | United States |
| Employees | 30 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.9M | 46.9M |
| IPO Year | N/A | 1998 |
| Metric | SCLX | HGBL |
|---|---|---|
| Price | $6.57 | $1.39 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 30.1K | ★ 83.7K |
| Earning Date | 05-13-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.10 |
| Revenue | N/A | ★ $20,129,000.00 |
| Revenue This Year | N/A | $10.19 |
| Revenue Next Year | $749.70 | $8.51 |
| P/E Ratio | ★ N/A | $13.50 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.18 | $1.13 |
| 52 Week High | $34.27 | $2.32 |
| Indicator | SCLX | HGBL |
|---|---|---|
| Relative Strength Index (RSI) | 30.61 | 55.98 |
| Support Level | $4.56 | $1.23 |
| Resistance Level | $7.50 | $1.44 |
| Average True Range (ATR) | 0.64 | 0.08 |
| MACD | -0.13 | 0.02 |
| Stochastic Oscillator | 0.00 | 71.19 |
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
Heritage Global Inc values and monetizes industrial and financial assets by providing acquisition, disposition, valuation, and lending services for surplus and distressed assets. It aids in facilitating the economy by diverting useful industrial assets from landfills and operating a supply chain by overseeing the post-sale account activity of financial assets. The group operates in four segments namely Auction and Liquidation; Refurbishment and Resale; Brokerage and Specialty Lending. It generates maximum revenue from the Auction and Liquidation segment. The Auction and Liquidation segment, through HGP, operates as a full-service auction, appraisal, and asset advisory firm, including the acquisition of turnkey manufacturing facilities and used industrial machinery and equipment.